Lymphoma Therapeutics: A Market Snapshot
The global lymphoma therapeutics market is set to witness an impressive growth, primarily due to high unmet clinical needs associated with the disease and emerging product launches. The NHL therapeutics market is the major market among global lymphoma therapeutics market.
The promising drug pipeline and evolving treatment patterns are the factors that would largely drive the market growth.
The market is expected to register substantial growth in mid-term due to the various strategies adopted by the leading industry players.
Recently, EMD Serono entered into an agreement with Pfizer to co-promote its anaplastic lymphoma kinase (ALK) inhibitor Xalkori in the U.S. market.
The global Lymphoma Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Lymphoma Therapeutics in these regions, from 2012 to 2022 (forecast), covering
North America, Europe, China, Japan, Southeast Asia, India.
Global Lymphoma Therapeutics market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
F. Hoffmann-La Roche AG, Eli Lilly, Pfizer Inc., Bristol-Myers Squibb (BMS), Celgene Corp., GlaxoSmithKline, Accredo Health Group, Baxter International, Eisai Pharmaceuticals, Genelabs Technologies, Merck & Co.
Category: Market Research Publishers and RetailersCompany about: Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns. Our online stage, KMInsights.com, offers an unmatched gathering of market examination reports, organization audits, databooks, articles, periodical distributions, databases, on-line endorser administrations, and a great deal m ...
For more information: